{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-26-000008","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2026-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.806889+00:00","generated_at":"2026-05-16T10:05:13.041668+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmunityBio reports preliminary FY2025 ANKTIVA revenue ~$113M, up ~700% YoY, and Saudi approval for NSCLC","bullets":["Preliminary FY2025 net product revenue ~$113.0M, ~700% YoY increase; Q4 2025 revenue ~$38.3M, up 20% QoQ and 431% YoY.","ANKTIVA unit sales volume grew 750% in 2025 vs 2024; quarter-over-quarter unit growth 54% during FY2025.","Saudi FDA approved ANKTIVA + checkpoint inhibitor for metastatic NSCLC (first global approval for this indication) and + BCG for NMIBC CIS.","Phase 2b QUILT-2.005 trial enrollment ahead of expectations; full enrollment anticipated in H1 2026.","Estimated cash, cash equivalents and marketable securities of $242.8M as of Dec 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-26-000008","json":"https://secwatch.observer/filing/0001326110-26-000008.json","markdown":"https://secwatch.observer/filing/0001326110-26-000008.md","text":"https://secwatch.observer/filing/0001326110-26-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000008/0001326110-26-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000008/ibrx-20260115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:05:13.041668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}